Related Experiment Video
Updated: Jan 22, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition
1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Insights
Warfarin use in Chronic Kidney Disease (CKD) patients presents challenges due to altered pharmacokinetics. Understanding these changes is key to optimizing warfarin therapy and improving patient outcomes in CKD.
Area of Science:
- Nephrology
- Pharmacology
- Cardiology
Background:
- Chronic Kidney Disease (CKD) is a global health issue.
- CKD patients face increased cardiovascular risks, necessitating anticoagulation.
- Warfarin use in CKD is debated due to potential complications.
Purpose of the Study:
- To review warfarin use, dosing, and outcomes in CKD patients.
- To explore pharmacokinetic factors influencing warfarin response in CKD.
Main Methods:
- Literature search and review of studies on warfarin in CKD.
- Analysis of data on warfarin metabolism, transport, and pharmacokinetics.
Main Results:
- Altered warfarin pharmacokinetics in CKD include changes in protein binding and nonrenal clearance.
- Metabolism and disposition of warfarin metabolites are affected in CKD.
- These pharmacokinetic changes contribute to variable warfarin response.
Conclusions:
- Warfarin's efficacy and safety in advanced CKD require further investigation.
- Synthesized findings aim to guide optimized warfarin therapy for CKD patients.
Background:
Chronic Kidney Disease (CKD) is a prevalent worldwide health problem. Patients with CKD are more prone to developing cardiovascular complications such as atrial fibrillation and stroke. This warrants the use of oral anticoagulants, such as warfarin, in this population. While the efficacy and safety of warfarin in this setting remain controversial, a growing body of evidence emphasizes that warfarin use in CKD can be problematic. This review discusses 1) warfarin use, dosing and outcomes in CKD patients; and 2) possible pharmacokinetic mechanisms for altered warfarin dosing and response in CKD.
Methods:
Structured search and review of literature articles evaluating warfarin dosing and outcomes in CKD. Data and information about warfarin metabolism, transport, and pharmacokinetics in CKD were also analyzed and summarized.
Results:
The literature data suggest that changes in warfarin pharmacokinetics such as protein binding, nonrenal clearance, the disposition of warfarin metabolites may partially contribute to altered warfarin dosing and response in CKD.
Conclusion:
Although the evidence to support warfarin use in advanced CKD is still unclear, this synthesis of previous findings may help in improving optimized warfarin therapy in CKD settings.
More Related Videos
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
10:51A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
Published on: December 2, 2014
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment